Ethics of Liver Transplantation: The Role of the Anesthesiologist

2018 ◽  
Vol 22 (2) ◽  
pp. 229-236 ◽  
Author(s):  
James M. West

Anesthesiologists have clearly established their place in the history of medical ethics. Our involvement goes back to 1966 when Henri Beecher published his landmark paper on research and informed consent. Participation in the ethics of transplantation is no less important than our previous work. Organ transplant has been life saving for many but also has given rise to many misunderstandings not just from the public but also among our own colleagues. These include methods of allocation and donation, the role that affluence may play in receiving an organ, the definition of death and donation after circulatory death. As perioperative physicians and important members of the transplant team, anesthesiologists are expected to participate in all aspects of care including ethical judgments. This article discusses some of the issues that seem to cause the most confusion and angst for those of us involved in both liver transplantation and in the procurement of organs. It will discuss the definition of death, donation after circulatory death, the anesthesiologists’ role on the selection committee, living donor liver transplantation, and transplantation of patients with alcohol-related liver disease.

2019 ◽  
Vol 53 (10) ◽  
pp. 981-990 ◽  
Author(s):  
Margaret R. Jorgenson ◽  
Jillian L. Descourouez ◽  
Daniel C Felix ◽  
Bret M. Hanlon ◽  
Glen E. Leverson ◽  
...  

Background: Studies suggest that rabbit-antithymocyte globulin (rATG) decreases biliary complications (BCs) after donation-after-circulatory-death-donor liver transplantation (DCD LTx), but safety data are lacking. Objective: Our aim was to assess the safety of rATG for this indication. The secondary end point was efficacy of rATG for this indication. Methods: Adult recipients of DCD LTx were divided into 2 cohorts: protocolized use of rATG in the modern era (July 1, 2013, to December 31, 2016) and a historical control without rATG (January 1, 2005, to June 30, 2013). Incidence of infection, leukopenia, and thrombocytopenia were compared for the safety assessment, incidence of BCs, ischemic cholangiopathy (IC), and transplant outcomes for the efficacy assessment. Results: A total of 83 patients met inclusion criteria: 42 in the historical cohort and 41 in the modern cohort. The modern cohort had significantly fewer bacterial infections at 3 months (historical 54.8% vs modern 23%; P = 0.004) and 1 year (historical 62.1% vs modern 34.2%, P = 0.004). The modern cohort also had fewer fungal infections at these time points (historical 33.3% and 47.9% vs modern 15% and 15%; P = 0.001). There were no significant differences in platelet or white blood cell reduction between groups. There was a nonsignificant, but numerical, trend toward reduced IC/BC in the modern cohort at 1 year (IC: historical 30.1% vs modern 13.2%, P = 0.08; BC: historical 51% vs modern 37.5%, P = 0.13). There was no difference in graft/patient survival. Conclusion and Relevance: Our data suggest no major safety issues with rATG in DCD LTx. Our study should ease clinical apprehension surrounding rATG use for this indication. Future prospective studies are needed to further evaluate the role of rATG and its impact on efficacy end points.


2020 ◽  
Vol 86 (2) ◽  
Author(s):  
Chiara Lazzeri ◽  
Manuela Bonizzoli ◽  
Fabio Marra ◽  
Paolo Muiesan ◽  
Davide Ghinolfi ◽  
...  

2019 ◽  
Vol 13 (2) ◽  
pp. 212-215
Author(s):  
Keita Shimata ◽  
Tomoaki Irie ◽  
Masashi Kadohisa ◽  
Seiichi Kawabata ◽  
Sho Ibuki ◽  
...  

2020 ◽  
Vol 14 (04) ◽  
pp. 408-410 ◽  
Author(s):  
Muhammed Rasid Aykota ◽  
Tugba Sari ◽  
Sevda Yilmaz

Orthotopic liver transplantation is a life-saving procedure for patients with end-stage liver failure. However, Acinetobacter baumannii infections and acute rejection are important causes of morbidity and mortality following transplants. Here we present a case report of a cadaveric donor liver transplantation with infectious complications detected after transplantation. The patient was a 64-year-old female. Because of non-alcoholic steatohepatitis due to hepatic insufficiency (model for end-stage liver disease (MELD): 12; Child-Pugh: 9B), liver transplantation from a cadaveric donor was performed. Following the transplantation, the patient developed a blood stream infection, urinary tract infection (UTI) and postoperative wound infection from biliary leakage. A. baumannii was isolated from blood, urine and wound cultures. Imipenem (4×500 mg), tigecycline (2×50 mg) and phosphomycin (4×4 g) were administered intravenously (IV). On the 14th day of treatment, the bile fistula closed and there was no bacterial growth in blood and urine cultures. The patient was discharged with full recovery. The duration of a transplant patient’s hospital stay, intensive care unit stay, invasive interventions, blood transfusions and immunosuppressive treatments cause an increased risk of extensively drug-resistant (XDR) A. baumannii infections, and a high mortality rate is seen despite antibiotic treatment. Phosphomycin, used in combination therapy, may be an alternative in the treatment of XDR pathogens in organ transplant patients, due to its low side effect profile and lack of interaction with immunosuppressives.


JAMA Surgery ◽  
2014 ◽  
Vol 149 (1) ◽  
pp. 77 ◽  
Author(s):  
Johnny C. Hong ◽  
Robert Venick ◽  
Hasan Yersiz ◽  
Prawat Kositamongkol ◽  
Fady M. Kaldas ◽  
...  

2020 ◽  
Vol 272 (5) ◽  
pp. 759-765
Author(s):  
Matteo Mueller ◽  
Marit Kalisvaart ◽  
Joanne O‘Rourke ◽  
Shishir Shetty ◽  
Alessandro Parente ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document